AR070467A1 - Inhibidores de quinasa de pirrolopirazina - Google Patents
Inhibidores de quinasa de pirrolopirazinaInfo
- Publication number
- AR070467A1 AR070467A1 ARP090100620A ARP090100620A AR070467A1 AR 070467 A1 AR070467 A1 AR 070467A1 AR P090100620 A ARP090100620 A AR P090100620A AR P090100620 A ARP090100620 A AR P090100620A AR 070467 A1 AR070467 A1 AR 070467A1
- Authority
- AR
- Argentina
- Prior art keywords
- phenyl
- lower alkyl
- haloalkyl
- heterocycloalkyl
- heteroaryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
Abstract
Inhiben la JAK y la SYK y son utiles para el tratamiento de enfermedades inflamatorias y autoinmunes. Reivindicacion 1: Un compuesto de la formula 1 en la que: R es R1, R2, R3 o R4; R1 es alquilo inferior, alcoxi inferior, fenilo, bencilo, heteroarilo, cicloalquilo, heterocicloalquilo o cicloalquilalquilo, opcionalmente sustituido por uno o más R1a; R1a es R1b o R1c; R1b es halogeno, oxo, hidroxi o -CN; R1c es -C(=O)O(R1f), -C(=O)(CH2)m(R1e), -O(CH2)m(R1e), -S(R1f), -S(O)2(R1f) o -S(=O)(R1f), alquilo inferior, alcoxi inferior, amino, amido, haloalquilo inferior, fenilo, heteroarilo, cicloalquilo, heterocicloalquilo, cicloalquiloxi o heterocicloalquiloxi opcionalmente sustituido por uno o más R1d; R1d es H, halogeno, hidroxi, alquilo inferior, amino, alcoxi inferior o haloalquilo inferior; R1e es H, alquilo inferior, alcoxi inferior, ciano, haloalquilo inferior, fenilo, heteroarilo, cicloalquilo o heterocicloalquilo; R1f es H, alquilo inferior, haloalquilo inferior, fenilo, heteroarilo, cicloalquilo o heterocicloalquilo; m es el numero 0, 1 o 2; R2 es N(R2a)2; cada R2a es con independencia H o R2b; cada R2b es con independencia alquilo inferior, fenilo, heteroarilo, cicloalquilo, heterocicloalquilo o heterocicloalquil-alquileno, opcionalmente sustituido por uno o más R2c; R2c es R2d o R2e; R2d es halogeno, oxo o hidroxi; R2e es -N(R2g)2, -C(=O)(R2g), -C(=O)O(R2g), -C(=O)N(R2g)2, -N(R2g)C(=O)(R2g), -S(=O)2(R2g), -S(O)2N(R2g)2, alquilo inferior, alcoxi inferior, haloalquilo inferior, fenilo, heteroarilo, heteroariloxi, cicloalquilo o heterocicloalquilo, opcionalmente sustituido por uno o más R2f; cada R2f es con independencia H, halogeno, alquilo inferior, alcoxi inferior, haloalquilo inferior; cada R2g es con independencia H, alquilo inferior, alcoxi inferior, haloalquilo inferior o fenilo; R3 es -C(=O)R3a; R3a es alquilo inferior, alcoxi inferior, fenilo o N(R3b)2; cada R3b es con independencia H o alquilo inferior; R4 es -O(R4a); R4a es H o R4b; R4b es alquilo inferior, fenilo, bencilo, haloalquilo inferior, cicloalquilo, heterocicloalquilo, heteroarilo, opcionalmente sustituido por uno o más R4c; R4c es halogeno, hidroxi, alquilo inferior, haloalquilo inferior o alcoxi inferior; Q4 es Q4a o Q4b; Q4a es H, hidroxi, ciano o halogeno; Q4b es alquilo inferior, alquenilo inferior, alquinilo inferior, hidroxialquilo inferior, amino o haloalquilo inferior, opcionalmente sustituido por uno o más Q4c; Q4c es Q4d o Q4e; cada Q4d es con independencia halogeno, hidroxi o ciano; cada Q4e es con independencia alquilo inferior, haloalquilo inferior, alcoxi inferior, amino, cicloalquilo, fenilo, heterocicloalquilo o heteroarilo, opcionalmente sustituido por uno o más Q4f; cada Q4f es con independencia hidroxi, halogeno, alquilo inferior, alquenilo inferior, oxo, haloalquilo inferior, alcoxi inferior, hidroxialquilo inferior o amino; con la condicion de que cuando R es R4, R4 es -O(R4a), R4a es H y Q4 es Q4a, entonces Q4a no sea H; o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3103508P | 2008-02-25 | 2008-02-25 | |
US14651409P | 2009-01-22 | 2009-01-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR070467A1 true AR070467A1 (es) | 2010-04-07 |
Family
ID=40514045
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP090100620A AR070467A1 (es) | 2008-02-25 | 2009-02-23 | Inhibidores de quinasa de pirrolopirazina |
Country Status (18)
Country | Link |
---|---|
US (1) | US8119636B2 (es) |
EP (1) | EP2247593B1 (es) |
JP (1) | JP5284377B2 (es) |
KR (1) | KR20100114095A (es) |
CN (1) | CN101952296B (es) |
AR (1) | AR070467A1 (es) |
AT (1) | ATE519763T1 (es) |
AU (1) | AU2009218609A1 (es) |
BR (1) | BRPI0907928A2 (es) |
CA (1) | CA2713718A1 (es) |
CL (1) | CL2009000405A1 (es) |
IL (1) | IL206818A0 (es) |
MX (1) | MX2010009023A (es) |
PE (1) | PE20091738A1 (es) |
RU (1) | RU2010139284A (es) |
TW (1) | TW200942543A (es) |
WO (1) | WO2009106444A1 (es) |
ZA (1) | ZA201004942B (es) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2250172T3 (pl) * | 2008-02-25 | 2012-01-31 | Hoffmann La Roche | Pirolopirazynowe inhibitory kinazy |
JP5485178B2 (ja) * | 2008-02-25 | 2014-05-07 | エフ.ホフマン−ラ ロシュ アーゲー | ピロロピラジンキナーゼ阻害剤 |
CA2743134A1 (en) | 2008-11-10 | 2010-05-14 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
CA3013000C (en) | 2008-12-19 | 2022-12-13 | Vertex Pharmaceuticals Incorporated | Pyrazine derivatives useful as inhibitors of atr kinase |
US8518945B2 (en) | 2010-03-22 | 2013-08-27 | Hoffmann-La Roche Inc. | Pyrrolopyrazine kinase inhibitors |
US8481541B2 (en) | 2010-03-22 | 2013-07-09 | Hoffmann-La Roche Inc. | Pyrrolopyrazine kinase inhibitors |
WO2011143425A2 (en) | 2010-05-12 | 2011-11-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
JP2013529200A (ja) | 2010-05-12 | 2013-07-18 | バーテックス ファーマシューティカルズ インコーポレイテッド | Atrキナーゼ阻害剤として有用な化合物 |
JP2013526539A (ja) | 2010-05-12 | 2013-06-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | Atrキナーゼ阻害剤として有用なピラジン |
AU2011253021A1 (en) | 2010-05-12 | 2012-11-29 | Vertex Pharmaceuticals Incorporated | 2 -aminopyridine derivatives useful as inhibitors of ATR kinase |
EP2569313A1 (en) | 2010-05-12 | 2013-03-20 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
US8969356B2 (en) | 2010-05-12 | 2015-03-03 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
KR20130083387A (ko) * | 2010-05-20 | 2013-07-22 | 에프. 호프만-라 로슈 아게 | Syk 및 jak 억제제로서 피롤로피라진 유도체 |
JP2013529204A (ja) * | 2010-05-20 | 2013-07-18 | エフ.ホフマン−ラ ロシュ アーゲー | ピロロ[2,3−b]ピラジン−7−カルボキサミド誘導体とJAK及びSYK及び阻害剤としてのそれらの使用 |
CA2803802A1 (en) | 2010-06-23 | 2011-12-29 | Vertex Pharmaceuticals Incorporated | Pyrrolo- pyrazine derivatives useful as inhibitors of atr kinase |
EP2694498B1 (en) | 2011-04-05 | 2016-03-30 | Vertex Pharmaceuticals Incorporated | Aminopyrazine compounds useful as inhibitors of tra kinase |
CN103502249A (zh) * | 2011-05-17 | 2014-01-08 | 普林斯匹亚生物制药公司 | 作为酪氨酸激酶抑制剂的氮杂吲哚衍生物 |
US9309250B2 (en) | 2011-06-22 | 2016-04-12 | Vertex Pharmaceuticals Incorporated | Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors |
EP2723747A1 (en) | 2011-06-22 | 2014-04-30 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
US8822469B2 (en) | 2011-06-22 | 2014-09-02 | Vertex Pharmaceuticals Incorporated | Pyrrolo[2,3-B]pyrazines useful as inhibitors of ATR kinase |
WO2013030138A1 (en) * | 2011-09-01 | 2013-03-07 | F. Hoffmann-La Roche Ag | Pyrrolopyrazine kinase inhibitors |
EP2751088B1 (en) | 2011-09-30 | 2016-04-13 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
EP2751099B1 (en) | 2011-09-30 | 2017-06-14 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
EP3733185B1 (en) | 2011-09-30 | 2022-12-07 | Vertex Pharmaceuticals Incorporated | Treating non-small cell lung cancer with atr inhibitors |
WO2013049720A1 (en) | 2011-09-30 | 2013-04-04 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
PT2940017T (pt) | 2011-09-30 | 2019-10-31 | Vertex Pharma | Processos para a produção de compostos úteis como inibidores de atr quinase |
RU2662443C2 (ru) | 2011-11-01 | 2018-07-26 | Ф. Хоффманн-Ля Рош Аг | Имидазопиридазины |
US8846917B2 (en) | 2011-11-09 | 2014-09-30 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
WO2013071090A1 (en) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
WO2013071094A1 (en) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
US8841449B2 (en) | 2011-11-09 | 2014-09-23 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
EP2776420A1 (en) | 2011-11-09 | 2014-09-17 | Vertex Pharmaceuticals Incorporated | Pyrazine compounds useful as inhibitors of atr kinase |
KR20140108594A (ko) | 2012-01-10 | 2014-09-11 | 에프. 호프만-라 로슈 아게 | 피리다진 아미드 화합물 및 syk 저해제로서의 이의 용도 |
CN108478577A (zh) | 2012-04-05 | 2018-09-04 | 沃泰克斯药物股份有限公司 | 可用作atr激酶抑制剂的化合物及其组合疗法 |
MX2015002181A (es) * | 2012-08-21 | 2015-05-07 | Hoffmann La Roche | Pirrolo[2,3-b]pirazinas como inhibidores de syk. |
DK2904406T3 (en) | 2012-10-04 | 2018-06-18 | Vertex Pharma | METHOD OF DETERMINING THE ATR INHIBITION, INCREASED DNA DAMAGE |
EP2909202A1 (en) | 2012-10-16 | 2015-08-26 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
SI3808749T1 (sl) | 2012-12-07 | 2023-07-31 | Vertex Pharmaceuticals Incorporated | Pirazolo(1,5-A)pirimidini za uporabo kot zaviralci ATR kinaze pri zdravljenju rakavih bolezni |
WO2014143240A1 (en) | 2013-03-15 | 2014-09-18 | Vertex Pharmaceuticals Incorporated | Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase |
EP2997013A4 (en) * | 2013-05-14 | 2017-03-22 | 3M Innovative Properties Company | Pyridine- or pyrazine-containing compounds |
SI3077397T1 (sl) | 2013-12-06 | 2020-02-28 | Vertex Pharmaceuticals Inc. | 2-amino-6-fluoro-N-(5-fluoro-piridin-3-IL)pirazolo(1,5-A)pirimidin-3- karboksamidna spojina, koristna kot inhibitor kinaze ATR, njena priprava, različne trdne oblike in njeni radioaktivno označeni derivati |
PL3152212T3 (pl) | 2014-06-05 | 2020-06-15 | Vertex Pharmaceuticals Inc. | Radioznakowane pochodne związku 2-amino-6-fluoro-n-[5-fluoro-piridyn-3-ylo]-pirazolo[1,5-a]pirymidino-3-karboksamidu przydatne jako inhibitor kinazy atr, wytwarzanie tego związku i jego różnych postaci stałych |
SI3157566T1 (sl) | 2014-06-17 | 2019-08-30 | Vertex Pharmaceuticals Incorporated | Postopek za zdravljenje raka z uporabo kombinacije inhibitorjev CHK1 in ATR |
WO2017059357A1 (en) | 2015-09-30 | 2017-04-06 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of dna damaging agents and atr inhibitors |
US20170100396A1 (en) | 2015-10-07 | 2017-04-13 | F. Hoffmann-La Roche Ag | Pyrrolopyrazine derivatives for use in the treatment, amelioration or prevention of influenza |
MX2022007518A (es) | 2019-12-20 | 2022-09-19 | Pfizer | Derivados bencimidazol. |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR0017038A (pt) | 1999-12-24 | 2003-01-07 | Aventis Pharma Ltd | Azaindóis |
GB0115109D0 (en) | 2001-06-21 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
DE60316542T2 (de) | 2002-03-28 | 2008-07-03 | Eisai R&D Management Co., Ltd. | 7-azaindole als inhibitoren c-jun n-terminaler kinasen zur behandlung neurodegenerativer störungen |
CA2550361C (en) * | 2003-12-19 | 2014-04-29 | Prabha Ibrahim | Compounds and methods for development of ret modulators |
NZ555566A (en) * | 2004-11-22 | 2009-12-24 | Vertex Pharma | Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases |
US7456289B2 (en) * | 2004-12-31 | 2008-11-25 | National Health Research Institutes | Anti-tumor compounds |
CL2007002617A1 (es) | 2006-09-11 | 2008-05-16 | Sanofi Aventis | Compuestos derivados de pirrolo[2,3-b]pirazin-6-ilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar inflamacion de las articulaciones, artritis reumatoide, tumores, linfoma de las celulas del manto. |
WO2008063888A2 (en) * | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
PE20081581A1 (es) | 2006-12-21 | 2008-11-12 | Plexxikon Inc | COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA |
EP2247592B1 (en) * | 2008-02-25 | 2011-08-31 | F. Hoffmann-La Roche AG | Pyrrolopyrazine kinase inhibitors |
PL2250172T3 (pl) * | 2008-02-25 | 2012-01-31 | Hoffmann La Roche | Pirolopirazynowe inhibitory kinazy |
-
2009
- 2009-02-16 KR KR1020107018679A patent/KR20100114095A/ko not_active Application Discontinuation
- 2009-02-16 JP JP2010548070A patent/JP5284377B2/ja not_active Expired - Fee Related
- 2009-02-16 WO PCT/EP2009/051759 patent/WO2009106444A1/en active Application Filing
- 2009-02-16 AU AU2009218609A patent/AU2009218609A1/en not_active Abandoned
- 2009-02-16 MX MX2010009023A patent/MX2010009023A/es not_active Application Discontinuation
- 2009-02-16 EP EP09714560A patent/EP2247593B1/en not_active Not-in-force
- 2009-02-16 BR BRPI0907928-9A patent/BRPI0907928A2/pt not_active IP Right Cessation
- 2009-02-16 CN CN2009801062407A patent/CN101952296B/zh not_active Expired - Fee Related
- 2009-02-16 AT AT09714560T patent/ATE519763T1/de not_active IP Right Cessation
- 2009-02-16 RU RU2010139284/04A patent/RU2010139284A/ru unknown
- 2009-02-16 CA CA2713718A patent/CA2713718A1/en not_active Abandoned
- 2009-02-20 US US12/378,837 patent/US8119636B2/en not_active Expired - Fee Related
- 2009-02-23 TW TW098105680A patent/TW200942543A/zh unknown
- 2009-02-23 AR ARP090100620A patent/AR070467A1/es unknown
- 2009-02-23 PE PE2009000261A patent/PE20091738A1/es not_active Application Discontinuation
- 2009-02-23 CL CL2009000405A patent/CL2009000405A1/es unknown
-
2010
- 2010-07-05 IL IL206818A patent/IL206818A0/en unknown
- 2010-07-13 ZA ZA2010/04942A patent/ZA201004942B/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP2247593B1 (en) | 2011-08-10 |
TW200942543A (en) | 2009-10-16 |
CL2009000405A1 (es) | 2010-02-26 |
PE20091738A1 (es) | 2009-11-13 |
US8119636B2 (en) | 2012-02-21 |
MX2010009023A (es) | 2010-09-07 |
ATE519763T1 (de) | 2011-08-15 |
WO2009106444A1 (en) | 2009-09-03 |
EP2247593A1 (en) | 2010-11-10 |
JP2011513263A (ja) | 2011-04-28 |
ZA201004942B (en) | 2011-12-28 |
JP5284377B2 (ja) | 2013-09-11 |
CA2713718A1 (en) | 2009-09-03 |
US20090215785A1 (en) | 2009-08-27 |
AU2009218609A1 (en) | 2009-09-03 |
IL206818A0 (en) | 2010-12-30 |
BRPI0907928A2 (pt) | 2015-07-28 |
RU2010139284A (ru) | 2012-04-10 |
KR20100114095A (ko) | 2010-10-22 |
CN101952296A (zh) | 2011-01-19 |
CN101952296B (zh) | 2013-08-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR070467A1 (es) | Inhibidores de quinasa de pirrolopirazina | |
AR070468A1 (es) | Pirrolopirazinas inhibidores de quinasa | |
AR106744A2 (es) | Formas cristalinas de un compuesto de bifenilo | |
PE20071001A1 (es) | Derivados de 1-(azolin-2-il)-amino-1-fenil-2-hetaril-etano con actividad pesticida | |
AR036095A1 (es) | Compuestos de pirazina que actuan como ligandos del receptor de 5-ht | |
AR105836A1 (es) | Compuestos y composiciones útiles para tratar trastornos relacionados con ntrk | |
AR064279A1 (es) | Compuestos basados en la 4-fenil-6-(2,2,2-trifluoro-1- feniletoxi) pirimidina y metodos de uso de los mismos | |
AR080699A1 (es) | Pirrolopirazinas como inhibidores de jak y syk | |
CY1118128T1 (el) | Αρυλ διϋδροπυριδινονες και πιπεριδiνονες ως αναστολεις του mgat2 | |
AR059087A1 (es) | Derivados de pirimidina como inhibidores de pi-3 quinasa , uso de los mismos y composiciones farmaceuticas. | |
AR078520A1 (es) | Compuesto heterociclico y su uso para el control de una plaga de artro-podos | |
ES2540851T3 (es) | Compuesto de ciclopropano | |
AR085607A1 (es) | Inhibidores de la mst1 quinasa y metodos para su utilizacion | |
CR9690A (es) | 3-acilaminobenzanilidas insecticidas | |
PE20141581A1 (es) | 3-pirmidin-4-il-oxazolidin-2-onas como inhibidores de la idh mutante | |
AR056536A1 (es) | Compuestos de 2-amino-5- [4-(difluormetoxi)fenil]-5-fenilimidazolona como inhibidores de la beta secretasa (bace) | |
AR078462A1 (es) | Inhibidores macrociclicos de la replicacion de virus de la hepatitis c | |
AR060807A1 (es) | Derivados de arilaminopiridina heteroaril - susutituidos como inhibidores de mek | |
AR077977A1 (es) | Compuestos y composiciones como inhibidores de cinasa de proteina | |
BRPI0721113A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, método para prevenir, tratar ou melhorar doenças ou condições dérmicas ou distúrbios | |
CO6321266A2 (es) | Inhibidores limk2 compuestos de los cuales estan hechos y metodologia de uso | |
ES2778898T3 (es) | Compuestos inhibidores de la autotaxina | |
AR103742A1 (es) | Derivados de trifluorometilpropanamida | |
AR065583A1 (es) | Compuestos macrociclicos y composicion farmaceutica | |
AR060912A1 (es) | Benzamidinas insecticidas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |